Abecma, Breyanzi, I-CARYKTI, UKymriah, UTecartus, Yeskarta
I-CAR T Cell Therapy Esekelwe Kubantu: Ukuphumelela kanye Nezinselele
Isingeniso Esizindeni se-oncology, i-immunotherapy isivele njengendlela yokuqala, esebenzisa amasosha omzimba ukuze alwe nezimila eziyingozi. Kunezindlela eziningi ze-immunotherapeutic, kepha i-Chimeric Antigen Rece.
Breyanzi, I-Juno Therapeutics, I-B-cell lymphoma enkulu, I-LBCL, Ukuguqula
I-Lisocabtagene maraleucel igunyazwe yi-FDA yokwelashwa komugqa wesibili we-B-cell lymphoma enkulu
Julayi 2022: I-Lisocabtagene maraleucel (i-Breyanzi, i-Juno Therapeutics, Inc.) igunyazwe yi-Food and Drug Administration ezigulini ezikhulile ezine-B-cell lymphoma (LBCL) ezinesifo esingavumelani ne-chemoi yomugqa wokuqala.
I-BMS, Breyanzi, Ukwelashwa kwe-CAR - T Cell, ISIMOTO SEMOTO, Ukwelashwa kwenqola, USFDA
IBreyanzi - Ukwelashwa okusha kwe-CAR T-Cell kusuka ku-BMS
Julayi 2021: I-Breyanzi (Lisocabtagene maraleucel; liso-cel), i-CD19-directed chimeric antigen receptor (CAR) T cell treatment eyakhiwe nguBristol Myers Squibb (BMS), ivunywe yi-US Food and Drug Administration (US.).